98P Neo-CheckRay, radiation therapy and adenosine pathway blockade to potentiate benefit of immuno-chemotherapy in early stage luminal B breast cancer: Results of the safety run-in phase

Luminal B breast cancer (BC) is characterised by an overall lower immunogenicity compared to non-luminal BC subtypes. The Neo-CheckRay trial investigates the use of stereotactic body radiation therapy (SBRT) directed to the primary tumour and the adenosine pathway inhibitor oleclumab to improve response to neo-adjuvant immuno-chemotherapy. The trial consists of a safety run-in followed by a randomized phase II trial. Here, we present the results of the safety run-in.